With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

Several victims of an avalanche that hit Northern California's backcountry on Tuesday were connected to a private school for competitive skiers, the institution said.

Just last week, the agency rejected Moderna’s initial application, citing flaws in the company’s research design.

Moderna announced the change Wednesday, about a week after revealing that the FDA’s vaccine chief was refusing to review the ...

The FDA is changing course, now saying it will review Moderna's new mRNA flu vaccine. Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, ...

Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.

The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after all, resolving a dispute that had blocked the company’s application for the first-of-its-kind ...

Andrew Egger and Jonathan Cohn give their takes on the stunning back-and-forth at the FDA over Moderna’s new mRNA flu vaccine, why the agency initially refused to even review the application, and what ...

The FDA has accepted Moderna’s revised approach seeking full approval for the shot for adults aged between 50 and 64, and accelerated approval for those aged 65 and above, the company said, adding ...

Dow Jones Top Company Headlines at 7 PM ET: FDA Reverses Course and Will Now Review Moderna's Flu Shot | Nvidia ... The company's mRNA flu shot, if approved, could be available for the 2026-27 flu ...

After public backlash, the FDA will review a new mRNA flu vaccine. That's good news, but its original rejection and other arbitrary decisions undermine U.S. leadership in biopharmaceutical innovation.